Peptides›Healing›PE 22-28

PE 22-28

/ 7-amino-acid fragment of B-cell-derived PEPITEM protein

SPECULATIVEN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · PEPITEM

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · 7-amino-acid fragment of B-cell-derived PEPITEM proteinCATEGORY · Healing

Academic research identified PEPITEM as a homeostatic regulator of T-cell trafficking in mouse models of autoimmunity. No human trials have been published.

§ B · Mechanism of action

PE 22-28 (PEPITEM) is a 7-amino-acid fragment of the B-cell-secreted protein 14-3-3ζδ. In murine work, it was reported to restrict T-cell trafficking into inflamed tissue, suggesting potential application in autoimmune inflammation.

§ C · Human clinical evidence

No human clinical trial data has been published. Evidence is restricted to mouse models of rheumatoid arthritis and related inflammatory disease.

§ D · Primary literature

PubMed25894827Chimen M et al. — Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease · Nature Medicine · other-animalIdentified PEPITEM (PE 22-28) as a B-cell-derived peptide that regulates homeostatic T cell trafficking. Loss of PEPITEM activity is implicated in autoimmune and chronic inflammatory disease in mouse models.Limitations: Mechanistic and murine; no human therapeutic trials.2015

§ F · Safety signal

No human safety data exists. Preclinical work does not identify safety liabilities but also does not establish the long-term safety of therapeutic administration.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Popular-press claims about anti-aging or metabolic effects outrun the actual preclinical literature, which focuses on T-cell trafficking in autoimmune inflammation.